Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial